Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven pancreatic ductal adenocarcinoma. Intraductal papillary mucinous tumor of the pancreas (IPMT) with invasive components are eligible.~2. Macroscopically complete resection (R0 or R1 resection).~3. Patients aged from 18 to 79 years.~4. WHO performance status 0-1.~5. No prior radiotherapy and no previous chemotherapy.~6. Full recovery from surgery and patient able to receive chemotherapy: adequate oral nutrition of ≥1500 calories per day and free of significant nausea and vomiting.~7. Adequate hematologic function (Absolute neutrophil count ANC ≥1,500 cells/mm³, platelets ≥100 000 cells/mm³ and hemoglobin ≥10 g/L - possibly after transfusion -).~8. Serum total bilirubin ≤1.5 times the institutional upper limit of normal.~9. Creatinine level \<130 micromol/L (14.7 mg/L).~10. Patient of child-bearing potential (for female patient: study entry after a menstrual period and a negative pregnancy test) must agree to use two medically acceptable methods of contraception (one for the patient and one for the partner) during the study and for 4 months after the last study treatment intake for women and 6 months for men.~11. Interval since surgery between 21 and 84 days.~12. Patient information and signed informed consent.~13. Public or private health insurance coverage.~Exclusion Criteria:~1. Other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, cystadenocarcinoma and malignant ampulloma.~2. Metastases (including ascites or malignant pleural effusion).~3. Macroscopic incomplete tumor removal (R2 resection).~4. CA 19-9 \> 180 U/ml within 21 days of registration on study.~5. No heart failure or coronary heart disease symptoms.~6. No major comorbidity that may preclude the delivery of treatment or active infection (HIV or chronic hepatitis B or C) or uncontrolled diabetes.~7. Pre-existing neuropathy, Gilbert's disease or genotype UGT1A1 \* 28 / \* 28.~8. Inflammatory disease of the colon or rectum, or occlusion or sub-occlusion of the intestine or severe postoperative uncontrolled diarrhea.~9. Concomitant occurrence of another cancer, or history of cancer except in situ carcinoma of the cervix treated or basal cell carcinoma or squamous cell carcinoma.~10. Fructose intolerance.~11. Persons deprived of liberty or under guardianship.~12. Psychological, familial, sociological or geographical condition potentially. hampering compliance with the study protocol and follow-up schedule.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Arm A GEMCITABINE (Type: ACTIVE_COMPARATOR): Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
- Arm B mFOLFIRINOX (Type: EXPERIMENTAL): Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)

Based on this trial design, predict the completion outcome and termination type (if applicable).